Craig Ritchie


Professor Craig Ritchie
Chair of the Psychiatry of Ageing and Director of the Centre for Dementia Prevention,
University of Edinburgh.






Research Interests
Prof Ritchie is the Professor of the Psychiatry of Ageing at the University of Edinburgh having moved from his role as Senior Lecturer in the Centre for Mental Health at Imperial College London in October 2014. He is also Director of the newly established Centre for Dementia Prevention at the University of Edinburgh
He is a leading authority on Clinical Trials in Dementia and has been senior investigator on over 30 drug trials of both disease modifying and symptomatic agents for that condition. This emerged from his ongoing clinical leadership of the MPAC (Metal Protein Attenuating Compound) pipeline for Prana Biotechnology dating back to 1998 when he worked as a Senior Visiting Research Fellow at the Mental Health Research Institute in Victoria, Australia. He has sat on advisory boards of numerous pharmaceutical companies, biotechs and clinical research organizations with an in interest in developing drugs and trials infrastructure for Alzheimer’s disease.
He has published extensively on the topics of dementia and delirium including clinical trials and meta-analyses. He sits on several advisory boards for major pharmaceutical and biotechnology companies as well as The Wellcome Trust and the Public Health Steering Group for the Alzheimer’s Society. He is also one of the leading editors in the Cochrane Collaboration’s Dementia Group with a particular specialism in Diagnostic Test Accuracy reviews and is Assistant Editor for the journal International Psychogeriatrics.
He is leading the PREVENT project; a major initiative nationally which will identify mid-life risks for later life dementia and characterize early changes of neurodegenerative disease through imaging, genetic, cognitive and biomarker analyses.
He also leads the EPAD (European Prevention of Alzheimer’s Dementia) Consortium which is an IMI funded, 5-year grant application to establish a Pan-European network of Trial Delivery Centers with supporting infrastructure to undertake a perpetual, Proof of Concept multi-arm trial secondary trial for secondary prevention of Alzheimer’s dementia. This work will be led from Edinburgh

Key Publications
Ritchie K, Carriere I, Berr C, Amieva H, Dartigues JF, Ancelin ML and Ritchie CW. (2016) The clinical picture of Alzheimer's disease in the decade before diagnosis: clinical and biomarker trajectories. J. Clin. Psychiatry. [Epub ahead of print] PubMed PMID: 26891108.
Ritchie CW, Molinuevo JL, Truyen L, Satlin A, Van der Geyten S and Lovestone S. (2016) European Prevention of Alzheimer's Dementia (EPAD) Consortium. Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project. Lancet Psychiatry 3: 179-186.
Huntington Study Group Reach2HD Investigators. (2015) Safety, tolerability, and efficacy of PBT2 in Hintington's disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol., 14: 39-47.
Noel-Storr AH, McCleery JM, Richard E, Ritchie CW, Flicker L, Callum SH, Davis D, Quinn TJ, Hyde C, Rutjes AW, Smailagic N, Marcus S, Black S, Blennow K, Brayne C, Fiorivanti M, Johnson JK, Kopke S, Schneider LS, Simmons A, Mattsson N, Zetterberg H, Bossuyt PM, Wilcock G and McShane R. (2014) Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Intiative. Neurology, 83: 364-373.
Ritchie C, Smailagic N, Noel-Storr AH, Takwoingi Y, Flicker L, Mason SE and McShane R. (2014) Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cogntive impairment (MCI). Cochrane Database Syst. Rev., 6:CD008782.